Hormone replacement therapy:where to now?
نویسندگان
چکیده
منابع مشابه
Postmenopausal Hormone Replacement Therapy— Where Are We Now?
More and more women are entering their postmenopausal years, requiring more training of women’s health care professionals and greater research efforts to further uncover the benefits and risks of hormone replacement therapy (HRT). In the Western world, menopause occurs at about 51.4 years, and currently close to 42 million women in the United States are older than 50 years [1]. With a life expe...
متن کاملHormone replacement therapy after the menopause--where are we now?
British Journal of General Practice, March 2005 companies are now established offering an n-of-1 trial service to HMOs so that costeffectiveness studies can be established in individual patients seeking long-term medical treatment. Barriers to the wider dissemination and implementation of n-of-1 trials include a lack of intellectual and administrative experience. The effort of setting up an n-o...
متن کاملMolecular replacement then and now
The `phase problem' in crystallography results from the inability to directly measure the phases of individual diffracted X-ray waves. While intensities are directly measured during data collection, phases must be obtained by other means. Several phasing methods are available (MIR, SAR, MAD, SAD and MR) and they all rely on the premise that phase information can be obtained if the positions of ...
متن کاملWillingness to pay for hormone replacement therapy.
This study addresses the question of willingness to pay (WTP) for hormone replacement therapy (HRT) in order to alleviate menopausal symptoms. The woman obtains utility from consumption of goods and health. The purchase of a treatment is represented as a shift in the health production function during the treatment period. The mean WTP for the HRT is estimated using a parametric and a non-parame...
متن کاملHormone replacement therapy.
HRT is indicated for the treatment of moderate ▪ to severe vasomotor and urogenital symptoms associated with menopause. HRT is not recommended for primary prevention of ▪ disease because of increased risk of other adverse events. The use of HRT increases the risk of stroke, venous ▪ thromboembolism (VTE) and gall bladder disease and combined oestrogen progestogen therapy is also associated with...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Australian Prescriber
سال: 2003
ISSN: 0312-8008,1839-3942
DOI: 10.18773/austprescr.2003.006